Inventor · disambiguated record
Lalgudi S. Harikrishnan
Also filed as: HARIKRISHNAN LALGUDI S
19 granted patents·3 pending applications·65 citations·filing 2002–2020
91Inventor score
Top patents by PatentIndex Score
22 records- 0190US7001911B2Fused cyclic modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 21, 2006·31 cites·21 claims
- 0287US7790770B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 7, 2010·10 cites·25 claims
- 0384US7888376B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 15, 2011·8 cites·17 claims
- 0479US8445676B2Pyrrolotriazine kinase inhibitorsPURANDARE ASHOK VINAYAK·Filed 2009·Granted May 21, 2013·5 cites·10 claims
- 0578US10053454B2Carbazole compounds useful as bromodomain inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 21, 2018·3 cites·5 claims
- 0678US7432267B2Fused cyclic modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Oct 7, 2008·2 cites·14 claims
- 0777US11660311B2Cyclic dinucleotides as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted May 30, 2023·2 cites·17 claims
- 0873US10292985B2TGF beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted May 21, 2019·1 cites·12 claims
- 0971US8304403B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2010·Granted Nov 6, 2012·2 cites·17 claims
- 1066US10336761B2TGFβ receptor antagonistBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 2, 2019·1 cites·6 claims
- 1161US11339185B2Cyclic dinucleotides as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted May 24, 2022·0 cites·11 claims
- 1258US10519187B2Cyclic dinucleotides as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 31, 2019·0 cites·70 claims
- 1356US12012374B2Agonists of ROR GAMMAtBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Jun 18, 2024·0 cites·10 claims
- 1456US11667663B2Cyclic dinucleotides as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 6, 2023·0 cites·3 claims
- 1551US8642576B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2012·Granted Feb 4, 2014·0 cites·14 claims
- 1650US2023295087A1AGONISTS OF ROR GAMMAtBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1749US2022306630A1AGONISTS OF ROR GAMMAtBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1848US10196387B2Carbazole compounds useful as bromodomain inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 5, 2019·0 cites·5 claims
- 1944US10744150B2Cyclic dinucleotides as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 18, 2020·0 cites·54 claims
- 2042US2018250303A1Tgf beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 2140US10399987B2TGF beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 3, 2019·0 cites·11 claims
- 2239US10683290B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 16, 2020·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Lalgudi S. Harikrishnan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →